The College of New Jersey Logo

Apply     Visit     Give     |     Alumni     Parents     Offices     TCNJ Today

Research Interests

1. Preparation of Novel Ring Systems Utilizing Parham Cycliacylation/Cyclialkylation Chemistry/Halogen-Lithium Exchange Reactions

During the late 1970’s, Parham and his group found that halogen-metal exchange reactions could be conducted on arene bromides (or iodides) with alkyllithium reagents at low temperatures (ca. -100 o C) functionalized with a variety of electrophilic groups [-CN, -COOH, -COOR, CONR2, -(CH2)n X] attached either directly to the aromatic ring or on a carbon tether adjacent to the exchangeable ring halogen] known to react with alkyllithium reagents at “normal” temperatures1.  The remarkable chemoselectivity observed for this reaction has made it possible to pursue the synthesis of compounds which would be exceedingly difficult to prepare by any other means.

imgD

While this powerful technique has been utilized to generate polycyclic ring systems of medicinal interest 2–3, this chemistry, known as the Parham cyclialkylation/cycliacylation reaction, continues to be studied due to its wide applicability and untapped potential for the synthesis of a wide variety of molecular systems3. Many of the ongoing efforts in my laboratory focus on synthetic methods development exploiting the selectivity of Parham chemistry to enable the preparation of novel polycyclic ring systems and highly substituted heterocyclic ring systems4,5.

img9

References

  1. Parham, W.E.; Bradsher, C.K. Acc. Chem. Res. 1982, 15, 300-305.
  2. Parham, W.E.; Bradsher, C.K.; Hunt, D.A. J. Org. Chem. 1978, 43, 1606-1607.
  3. For examples, see (a)  Hodgetts, K.J. Tetrahedron 2005, 61, 6860-6870. (b)  El Sheikh, S.;  Schmalz, H-G.; Curr. Opin. Drug Disc. Dev. 2004, 7, 882-895. (c) Sotomayor, N.; Lete, E. Curr. Org. Chem. 2003, 7, 275-300. (d) Ruiz, J.; Sotomayor, N.;  E. Lete, Org. Lett. 2003, 5, 1115-1117. (e) Chen, S.; Plotkin, M.; Spoors, G.P.; Tetrahedron Lett. 2000, 41, 2269-2273.  (f)  Larsen, S.D. Synlett. 1997, 1013-1014.; (g)  Monte, A.P.;   Maronalewicka, D.; Parker, M.A.; Wainscot, D.B.; Nelson, D.L.; Nichols, D.E. J. Med. Chem. 1996, 39, 2953-2961. (h) Couture, A.; Deniau, E.; Grandclaudon, P. J. Chem. Soc., Chem. Commun. 1994, 1329- 1330.
  4. Clarke A. J.; Hunt, D.A. “β-Nitrostyrenes as Electrophiles in Parham Cyclization Chemistry. Reaction with o-Lithiobenzonitrile“ Tetrahedron Lett. 2009, 50, 2949-2951.
  5. Hunt, D.A. “Solvent and Electronic Effects on Kinetics of Cyclization of Thermolabile Aryllithium Reagents. A Comparison Between 1-Bromo-2-(2-bromoethyl)benzene and 4,5-Dimethoxy-1-bromo-2-(2-bromoethyl)benzene,” Org. Commun. 2009 2, 60-65.
  6. Geherty, M.; Melnyk, J.; Chomsky, K.; Hunt, D.A. “Halogen-metal exchange reactions of bromoaryl-substituted β-lactams, Tetrahedron Lett., 2013, 54, 4934-4936.
  7. Farrokh, J.; Campos, C.; Hunt, D.A. “A Parham Cyclization approach to diaryl-fused seven-membered ring heterocyclic ketones,” Tetrahedron Lett., 2015, 56, 5245-5247.

2.  Medicinal Chemistry Studies I: Development of Small Molecule Proteasome Inhibitors

[with Professor Sudhir Nayak (Biology)]

Cellular proteins are maintained at appropriate levels through a balance between synthesis and degradation. The 26S proteasome helps maintain the appropriate balance through the targeted degradation of proteins and regulates the cell cycle, morphogenesis, differentiation, receptor modulation, DNA repair, and numerous others processes.  Since proteasomes are multi-protein complexes which selectively degrade cellular proteins no longer needed, inhibiting them in cancer cells can disrupt protein regulation, thereby leading to apoptosis (programmed cell death).  The recent discovery and FDA fast-tracking of PS-341, a synthetic small peptide boronate, and NPI-0052 for development of a treatment regimen for multiple myeloma 1 have served to spark inhibit this system as possible chemotherapeutic agents through targeted medicinal chemistry programs.2  The structural diversity between these compounds has led to speculation that there is differential selective inhibition of different proteolytic sites.  However, since little is known regarding the actual mode of action at the proteolytic target sites, this is a promising area for mode of action investigations.

               img3
              img4

Further, this is a fertile area for the design and development of small molecule inhibitors due to the paucity of compounds developed for chemotherapeutic targeting of the proteasome to date.

References

  1. Hideshima, T.; Bradner, J.E.; Wong, J.; Chauhan, D.; Richardson, P.; Shreiber, S.L.; Anderson, K.C. Proc. Natl. Acad. Sci. U.S.A. 2005, 102, 8567-8572.
  2. Joazeiro, C.A.P.; Anderson, K.C.; Hunter, T. Cancer Res. 2006, 66, 7840-7842.
  3. (a) Fiaschi, M.V; Nayak, S.; Tabakin, E.R.; Hunt, D.A. “Development of Small Molecule Proteasome Inhibitors,” Biotech 2008 Conference, Philadelphia, PA; November, 2008; Innovation Corridor Session I; (b)Fiaschi, M.V.; Stabenow, N.; Tabakin, E.R.; Hunt, D.A.; Nayak, S. “Development of Small Molecule Proteasome Inhibitors Using Caenorhabditis elegans,” 17th International C. elegans Meeting sponsored by the Genetics Society of America, University of California, Los Angeles, June 25, 2009; No. 1096A.
  4. Nayak, S.; Fiaschi, M.; King, D.; Tabakin, E. R.; Wood, L.; Hunt, D.A. “Development of small molecular proteasome inhibitors using a Caenorhabditis elegans screen” Int. J. Med. Chem. vol. 2014, 66, Article ID 237286, 14 pages, 2014. doi:10.1155/2014/237286.

3. Medicinal Chemistry Studies II: Development of Drugs for a Multi-Paradigm Therapy for Alzheimer ’s Disease

[with Professor Richard Egleton (Department of Pharmacology) and Dr. James Weinstein (Department of Neurosciences/Neurosurgery), Marshall University School of Medicine; Dr. Rasid Amin (Symmetry Biosciences, CEO/CSO), Andrew M. Fribley, Ph.D., Asst. Professor of Pediatrics; Associate, Dept. of Otolaryngology, Wayne State University School of Medicine, Division of Hematology/Oncology)]

Recent studies have indicated that there are multiple mechanisms involved in the development and progression of Alzheimer’s disease. These mechanisms can be categorized into one of five primary categories: (1) mitochondrial deficiency, leading to increased reactive oxygen species (ROS) formation, (2) an ”immune trigger” of Chlamydophila pneumoniae (90 % of Alzheimer’s patients are brain positive for C. pneumonia), (3) a neurotoxic inflammatory cascade driven by reactive Microglia, (4) generation of reactive oxygen species such as radicals, (5) excessive production of amyloid precursor protein (APP) and its derivative ß-amyloid, leading to synaptic dysfunction and neuronal loss, and (6) ApoE4 allele synthesis leading to toxic fragment formation (60-80% Alzheimer’s patients positive for the ApoE4 allelle). These five pathways combine to form a toxic cycle of neuronal damage and pathology leading to cognitive decline and the clinical presentation of Alzheimer’s disease, and ultimately death. To date most therapies for Alzheimer’s have concentrated on only one of the five causative factors of the disease progression and thus have had only limited success. Our hypothesis is that if a therapy is designed that will treat all five areas of Alzheimer’s disease, this should lead to a much more efficacious treatment strategy that should delay and hopefully potentially reverse the cognitive decline associated with Alzheimer’s. Though there have been considerable advances in drugs that are efficacious in vitro, there remain few viable options for in vivo effective compounds due to the presence of the blood brain barrier (BBB). The BBB plays a significant role in limiting drug entry to the brain and as such is a significant hurdle for Alzheimer’s therapies. The focus of this work is to develop drugs that can cross the BBB and treat one or more of the six primary etiologies of Alzheimer’s disease.

img17

References

  1. Weinstein, J.D.; Gonzalez, E.R.; Egleton, R.D.; Hunt, D.A. “The 10-patient screening protocol: a paradigm shift for evaluating pharmacotherapy for Alzheimer’s disease,” The Consultant Pharmacist 2013, 28, 443-454.
  2. Lin, M.T. and M.F. Beal, Mitochondrial dysfunction and oxidative stress in neurodegenerative diseases. Nature, 2006. 443 (7113): p. 787-95.
  3. Swerdlow, R.H. and S.M. Khan, A “mitochondrial cascade hypothesis” for sporadic Alzheimer’s disease. Med Hypotheses, 2004. 63(1): p. 8-20.
  4. Turrens, J.F., Mitochondrial formation of reactive oxygen species. J Physiol, 2003. 552(Pt 2): p. 335-44.
  5. Chlamydophila pneumoniae and the etiology of late-onset Alzheimer’s disease. J Alzheimers Dis, 2008. 13(4): p. 371-80.
  6. Gao, H.M. and J.S. Hong, Why neurodegenerative diseases are progressive: uncontrolled inflammation drives disease progression. Trends Immunol, 2008. 29(8): p. 357-65.
  7. Rojo, L.E., et al., Neuroinflammation: implications for the pathogenesis and molecular diagnosis of Alzheimer’s disease. Arch Med Res, 2008. 39(1): p. 1-16.
  8. Schwab, C. and P.L. McGeer, Inflammatory aspects of Alzheimer disease and other neurodegenerative disorders. J Alzheimers Dis, 2008. 13(4): p. 359-69.
  9. Anandatheerthavarada, H.K., et al., Mitochondrial targeting and a novel transmembrane arrest of Alzheimer’s amyloid precursor protein impairs mitochondrial function in neuronal cells. J Cell Biol, 2003. 161(1): p. 41-54.
  10. Devi, L., et al., Accumulation of amyloid precursor protein in the mitochondrial import channels of human Alzheimer’s disease brain is associated with mitochondrial dysfunction. J Neurosci, 2006. 26(35): p. 9057-68.
  11. Floden, A.M., S. Li, and C.K. Combs, Beta-amyloid-stimulated microglia induce neuron death via synergistic stimulation of tumor necrosis factor alpha and NMDA receptors. J Neurosci, 2005. 25(10): p. 2566-75.
  12. Lauren, J., et al., Cellular prion protein mediates impairment of synaptic plasticity by amyloid-beta oligomers. Nature, 2009. 457(7233): p. 1128-32.
  13. Manczak, M., et al., Mitochondria are a direct site of A beta accumulation in Alzheimer’s disease neurons: implications for free radical generation and oxidative damage in disease progression. Hum Mol Genet, 2006. 15(9): p. 1437-49.
  14. Nelson, T.J. and D.L. Alkon, Oxidation of cholesterol by amyloid precursor protein and beta-amyloid peptide. J Biol Chem, 2005. 280(8): p. 7377-87.
  15. Nikolaev, A., et al., APP binds DR6 to trigger axon pruning and neuron death via distinct caspases. Nature, 2009. 457(7232): p. 981-9.
  16. Agosta, F., et al., Apolipoprotein E epsilon4 is associated with disease-specific effects on brain atrophy in Alzheimer’s disease and frontotemporal dementia. Proc Natl Acad Sci U S A, 2009. 106(6): p. 2018-22.
  17. Bu, G., Apolipoprotein E and its receptors in Alzheimer’s disease: pathways, pathogenesis and therapy. Nat Rev Neurosci, 2009. 10(5): p. 333-44.
  18. Pardridge, W.M., Alzheimer’s disease drug development and the problem of the blood-brain barrier. Alzheimers Dement, 2009. 5(5): p. 427-32.

4. Michael Chemistry of 1,2-Cyclohexanediones

Michael chemistry of 1,3-diones has been well studied; however, far less is understood about the corresponding 1,2-diones. Previous work by the senior P.I. of this lab has illustrated the synthetic potential of 1,2-diones as precursors for the preparation of heterocycles1:

img7

The use of β-nitrostyrenes as the Michael acceptor in reactions with 1,2-cyclohexanedione has been recently reported2. In this study catalytic chiral bases were used, affording 5a or 5b. We have found that use of stochiometric + quantites of bases such as triethylamine or potassium carbonate lead to completely different product outcomes (compounds 3,4):

img11

References

  1. Hunt, D.A., US Patent 4,463,184, Process for the preparation of Carbofuran, (Union Carbide Agricultural Products), 1984.
  2. Simpkins, C.; Hunt, D.A. “The Michael addition of 1,2-cyclohexanedione to β-nitrostyrenes (I). The synthesis of 3-aryl-5,6-dihydrobenzofuran-7(4H)-ones,” Tetrahedron Lett. 2013, 54, 3373-3375.
  3. Ding, D.; Zhao, C-G.; Arman, H. Enantioselective synthesis of bicyclo[3,2,1]octan-8-ones using a tandem Michael-Henry reaction. Tetrahedron, 2010. 66, 4423-4427.

Student Research:

Grants

  • American Chemical Society Organic Chemistry Division – National Travel Grant (2012) – $600
  • Waters Corporation Academic Grant (2012) – $12,000
  • George and Rolfa Rogers Neurodegenerative Diseases Program of Marshall University (2011) – $20,000
  • NSF MRI CHE-1125993, Co-P.I.: Acquisition of a 400 MHz NMR Spectrometer for Undergraduate Research and Training (2011) – $261,086.
  • Dr. James Weinstein Foundation (co-P.I.’s: James Weinstein, M.D., Professor of Neurosurgery/ Neuroscience; Dr. Richard D. Egleton, Professor of Pharmacology) – Development of Drugs and Novel Transport Methods Enabling Penetration of the Blood-Brain Barrier for the Treatment of Alzheimer’s Disease (2010) – $50,000; (2011) – $75,000; (2012) – $205,000, (2013) – $29,500, (2014) – $37,000, (2015) – $30,000, (2017) – $10,000
  • School of Science Mini-Grant (2014) – $2,000
  • CHE-0922931 Co-P.I.: Acquisition of a Single Crystal X-ray Diffractometer for Undergraduate Research and Training (2009) – $242,200
  • Phi Kappa Phi Student Research Grant/Award (Sara Davis: A Convergent Synthesis of (+)-Isopestacin – 2008) – $500
  • Phi Kappa Phi Student-Faculty Research Grant/Award (Tyler Higgins: Functionalized 1,2-Cyclohexandiones as Michael Acceptors and Donors – 2012) – $250
  • Merck/AAAS Undergraduate Science Research Co-P.I. (2007-2009): Project: “Development of Small Molecule Proteasome Inhibitors” – Sudhir Nayak (Biology), David A. Hunt (Chemistry) – $60,000
  • TCNJ SOSA Grant Award: release time for academic year (2006-2007; 2007-2008; 2008-2009)
  • Bristol-Myers Squibb Undergraduate Research Award in Organic Chemistry – (Summers, 2006; 2007) – $10,000
  • National Starch Summer Research Grant (2007) – $5,000; 2 students (2008) – $10,000
  • TCNJ SURP Grant for 3 research students (2006) – $6,000; 1 student (2007) – $2,500
  • TCNJ MUSE Grant for 2 research students (2008; 2012, 2013) – $10,000
  • NASA (New Jersey Space Grant Consortium) Summer Research Award (2011) – $5,000

Students

Ms. Joanne Bertanozzi (2006 BMS Grant Recipient – Summer, 2006): Preparation of Novel Ring Systems Utilizing Parham Cycliacylation/ Cyclialkylation Chemistry (Summer, 2006)

Ms. Jessica Bocanegra; Michael Reactions with Knovenagel Adducts (Fall, 2013; Spring, 2014)

Ms. Catherine Campos; Studies Directed Towards Synthesis of Benzo-fused Oxepinones and Thiapanones (Spring 2006 – Spring, 2007)

Mr. Marc Casale; Mechanistic Studies of the Tandem Cyclization of Arylethylamino Acid Amides to Dihydroimidazoisoquinolin-3(2H)-ones (Fall, 2015-Spring, 2017)

Ms. Emily Cherney: Tandem Cyclization of Amino Acid Amides (Fall, 2005); Studies Toward a Novel Synthesis of Dihydroquinolines (Spring, 2006); Solvent Effects on the Preparation of 1,2,3,4-Tetrahydrobenzodiazapin-5-ones (Fall, 2006 – Spring, 2007)

Mr. Keith Chomsky (2007 BMS Grant Recipient – Summer, 2007): Lithium-Halogen Exchange Behavior in Bromo-Substituted 1,4-Diaryl β-Lactams (Spring, 2007; Summer, 2007; Fall, 2007 – Spring, 2008)

Mr. Adam Clarke; A Novel Synthesis of 1-Phenyl-2-Nitroindenes (Spring, 2006 – Fall, 2006); A Novel Synthesis of 2-Aminotetralins (Fall, 2005)

Mr. Tim Craven: Toward a Novel Synthesis of the Benzopyrazole Ring System via Condensation of Thermolabile Aryllithium Reagents and Diazodicarboxylate Esters (Summer, 2006)

Ms. Kate Davis: A New Route to Styryl Vinyl Ethers (Summer, 2007; Summer 2008; Fall, 2008 – Spring, 2009)

Ms. Sara Davis: A Total Synthesis of (+)-Isopestacin (Fall, 2007 – Fall, 2008)

Mr. Ryan DeAngelis: New Intramolecular Cyclization Strategies Built Around Novel Parham-type Substrates (Fall, 2012 – Spring, 2013, Summer, 2013); Investigations into an Unusal Aromatization Reaction of 1,2-Cyclohexandione Ethers (Fall, 2013; Spring, 2014)

Mr. John Farrokh (New Jersey Space Grant Consortium Fellow, Summer, 2011): Studies Directed Towards Synthesis of Benzo-fused Oxepinones and Thiapanones (Summer, 2011; Fall, 2011- Spring, 2012); Toward a Novel Synthesis of the Benzopyrazole Ring System via Condensation of Thermolabile Aryllithium Reagents and Diazo-dicarboxylate Esters (Fall, 2012; Spring, 2013)

Ms. Brittany Frazier: A Novel Synthesis of 2-Nitro-3-Arylindanones (Fall, 2009 – Spring, 2010)

Mr. Alex Fuchs: A Novel Synthesis of 2-Nitro-3-Arylindanones (Fall, 2009 – Spring, 2010)

Ms. Maryll Geherty: Lithium-Halogen Exchange Behavior in Bromo-Substituted 1,4-Diaryl β-Lactams (Summer, 2006)

Ms. Amber Gietter: A Novel Synthesis of 2-Nitro-3-Arylindanones (Fall, 2009 – Spring, 2010)

Mr. Andrew Glass: Tandem Michael Additions as a Strategy for Heterocyclic Ring Construction (Fall, 2014)

Mr. Alec Grossman: Cyclization Studies of Adducts from the Reaction of Functionalized Aryllithium Reagents and N-Substituted Isatoic Anhydrides (Fall, 2014)

Mr. Amit Gupta: Preparation of N-Pyrrolotin(IV) Compounds as Potential Molluscicides (Fall, 2015)

Mr. Tyler Higgins: Addition of 1,2-Cyclohexanedione to a Variety of Michael Acceptors (Summer, 2012; Fall, 2012; Spring, 2013); Preparation of Resveratrol Derivatives as Potential CNS Agents (Summer, 2013; Fall, 2013; Spring, 2014)

Mr. Hasan Kahn:  A Study of the Reaction of 1,3-Cyclohexanedione with Alcohols under Acid-Catalyzed Conditions (Fall, 2016)

Mr. Jay Kloskowski: A Study of the Reaction of 1,2-Cyclohexanedione with w-Halo-N-BOC Alkyl Amines (Fall, 2016-Fall,  2018)

Ms. Jenna Klubnick: Toward a Total Synthesis of (+)-Clavulazine (Fall, 2007- Spring, 2008)

Mr. Stephen Liang: A Study of the Reaction of b-Nitrostyrenes with omega-Haloalkyl Ammonium Salts (Fall, 2016-Spring, 2018)

Mr. Joe Macor: Tandem Cyclization of Amino Acid Amides (Summer, 2008)

Ms. Taylor Maney: Heck Reactions with Highly Functionalized Bromoarenes (Fall, 2013)
Preparation of Resveratrol Derivatives as Potential CNS Agents (Summer, 2013; Fall, 2013; Spring, 2014)

Mr. Jim Melnyk: Lithium-Halogen Exchange Behavior in Bromo-Substituted 1,4-Diaryl β-Lactams (Spring, 2007 – Spring, 2008)

Ms.Catherine Morgan: Preparation of Spin-labeled Inhibitors (SLIs) of Thermolysin (Fall, 2015)

Mr. Max Nazario:  Preparation of Spin-labeled Inhibitors (SLIs) of Thermolysin (Fall, 2015 – Fall 2017)

Ms. Christina Papanagapoulous: Tandem Cyclization of Amino Acid Amides (Fall, 2005,  Fall, 2006)
Cyclization Reactions of Amino Acid Amides (Spring, 2006); Reaction of Functionalized Aryllithium Reagents with Trialkyl- and Triarylboranes (Summer, 2006)

Mr. Mike Rosana (National Starch Grant Recipient – Summer, 2007): Expedient Preparation of 2-(5,6-Dihydro-4H-1,3-oxazin-2-yl)anilines (Summer, 2007 – Fall, 2007; Spring, 2008)

Ms. Marissa Rubenstein: Cyclization Strategies Built Around β-Nitro-substituted Systems as Michael Acceptors (Fall, 2012; Spring, 2013, Summer, 2013; Fall, 2013; Spring, 2014)

Mr. Zach St. John:  Dual Michael Additions of Biaryls Substituted with Dual Michael Acceptors (Fall, 2017)

Ms. Sarah Shoeb: o-Metallation of Benzyl Alcohols – A New Route to Indazoles (Fall, 2017)

Mr. Chad Simpkins: Michael Additions of β-Nitrostyrenes to1,2-Cyclohexanedione (Fall, 2010 – Spring, 2012; Summer, 2011)

Ms. Amy Solinski: Condensation/Aromatization Reactions with 1,2-Cyclohexanedione (Fall, 2013; Spring, 2014)

Ms. Sarah Thornton: Reaction of Functionalized Aryllithium Reagents with Isatoic Anhydrides (Fall, 2010 – Spring, 2012)

Ms. Erica Tabakin:(Merck/AAAS Research Undergraduate Research Fellow – Summer, 2008); Development of Small Molecule Proteasome Inhibitors (Summer, 2007; Summer 2008); Preparation of Some 4,6-difluoro-3-arylisobenzofuran-1(3H)-ones (Fall. 2008 – Spring, 2009)

Ms. Kelsey VanGelder (Merck/AAAS Research Undergraduate Research Fellow – Summer, 2009):
A Convergent Synthesis of (+)-Isopestacin (Summer, 2009; Fall, 2009; Spring, 2010-Spring, 2011)

Ms. Gina Wodarczyk: Preparation and Evaluation of Acylresveratrol Derivatives (Fall, 2017-Spring, 2018)

Ms. Lyndsay Wood (Merck/AAAS Research Undergraduate Research Fellow – Summer, 2009): Development of Small Molecule Proteasome Inhibitors (Summer, 2009)

Where Are They Now? Former Undergraduate Research Students

  • Catherine Campos  (2007) – Notre Dame (Ph.D. – Ashfeld); Asst. Prof., Longwood University
  • Emily Cherney (2007) – Scripps (Ph.D – Baran); Medicinal Chemistry- BMS (Princeton)
  • Maryl Geherty (2007) – Pittsburgh (Ph.D. – Nelson); Princeton (postdoc – Sorensen); Celgene – Process Chemistry
  • Joanne Bertonazzi (2008) – Pittsburgh (Ph.D. – Nelson); Old Bridge Chemicals – Old Bridge, NJ – Business Development
  • Keith Chomsky (2008) – Unknown
  • Adam Clarke (2008) – Bristol-Myers Squibb (medicinal chem)
  • Jenna Klubnick (2008) – Illinois [M.S. (2011) – organic; Burke]; Harvard (Center for Systems Biology, Weissleider); University of Pennsylvania Perelman School of Medicine (M.D.); Clinical Fellow in Medicine – Beth Israel Medical Center (Harvard)
  • Jim Melnyk (2008) – Delaware (Ph.D. organic/biochem; Grimes); UC-San Francisco (postdoc – Shokat)
  • Mike Rosana (2008) – Florida State (Ph.D. – Dudley); Associate Research Scientist – Altria
  • Tim Craven (2009) – NYU (Kirshenbaum)
  • Kate Davis (2009) – Lehigh (M.S.); Dow Chemical
  • Sara Davis (2009) – Hohenheim (M.S. – agriculture)
  • Erica Tabakin (2009) – Robert Wood Johnson Medical School (M.D.); Hospital of the University of Pennsylvania – Emergency Medicine
  • Brittany Frazier (2010) – Northeastern (M.S.N.)
  • Alex Fuchs (2010) – Connecticut (D.D.S.)
  • Amber Gietter (2010) – Delaware (Ph.D. – Watson, Don); Noramco, Wilmington, DE
  • Joe Macor (2010) – Illinois (Ph.D. – Girolami); University of Tokyo (postdoc – Kobyashi); MIT (postdoc – Buchwald); Research Scientist – Universal Display Corporation
  • Lyndsay Wood (2010) – Pennsylvania (organic; Winkler); Research Scientist – Dow Chemical
  • Kelsey VanGelder (2011) – Pennsylvania (organic; Kozlowski); Research Scientist – Glaxo Smith Kline
  • Chad Simpkins (2012) – Robert Wood Johnson Medical School (M.D.); Cooper Medical Center – Emergency Medicine
  • Sarah Thornton (2012) – Jefferson Medical College (M.D.); Tufts University/New England Eye Center
  • John Farrokh (2013) – UNC – Chapel Hill (M.S. organic, Johnson); Research Chemist,Symmetry Biosciences
  • Ryan DeAngelis (2014) – Cooper Medical School (NJ) (M.D.); Penn Medicine – Orthopedic Surgery
  • Tyler Higgins (2014) – Pennsylvania (organic; Winkler)
  • Marissa Rubenstein (2014) – Rutgers Dental School (D.D.S.)
  • Jessica Bocanegra (2015) – Vermont (organic, Schneebeli)
  • Taylor Maney (2015) – M.D. student, New York Medical College
  • Amy Solinski (2015) – Emory (organic, Wuest)
  • Andy Glass (2016) – Pennsylvania (organic, Winkler)
  • Alec Grossman (2016) – Lake Erie College of Osteopathic Medicine
  • Amit Gupta (2016) – New Jersey Medical School
  • Catherine Morgan (2016) – Research Chemist, Firmenich
  • Marc Casale (2017) – Mt. Sinai School of Medicine
  • Hasan Kahn (2017) – Hovione (organic process chemist)
  • Max Nazario (2017) – Syneos Health – Assistant Account Executive, Medical Communications
  • Stephen Liang (2018) – Albert Einstein College of Medicine
  • Jay Kloskowski (2018) – University of California, Riverside (organic, Larsen)
Top